- Liquid Biopsy
- Our technology enables the detection of the smallest amounts of DNA using probes, even in early cancers with low diagnostic rates and high sensitivity/specificity in array evaluations.
In particular, the methylation percentage can be quantified to provide a technology that enables cancer diagnosis.
- DNA Sequencing
- Base sequences in DNA generate changes of charge in several na units. These changes are detected and linked to reference sequences with AI-based sequencing platforms.
- Diagnostic Platform
- The diagnostic platform can be used for cancer diagnosis, biopharmaceutical performance testing and biopharmaceutical development, providing an optimal environment for multiple diagnoses or analysis of long sequences.
- Smart Healthcare System
- By applying DNA sequencing, we can develop specific biomarkers that can detect early cancers or adult diseases, and manage them from disease to prognosis through biosensor and AI algorithm diagnoses.